Int. J. Mol. Sci. 2010, 11(9), 3106-3121; doi:10.3390/ijms11093106
Article

Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer

1 School of Dentistry and Dental Research Institute, University of California Los Angeles, Los Angeles, CA, USA 2 Department of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, CA, USA 3 Department of Statistics, University of California Los Angeles, Los Angeles, CA, USA 4 Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA 5 Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA
* Author to whom correspondence should be addressed.
Received: 28 July 2010; in revised form: 25 August 2010 / Accepted: 27 August 2010 / Published: 2 September 2010
(This article belongs to the Special Issue Biomarkers)
PDF Full-text Download PDF Full-Text [464 KB, uploaded 2 September 2010 14:10 CEST]
Abstract: Lymph node involvement is the most important predictor of survival rates in patients with oral squamous cell carcinoma (OSCC). A biomarker that can indicate lymph node metastasis would be valuable to classify patients with OSCC for optimal treatment. In this study, we have performed a serum proteomic analysis of OSCC using 2-D gel electrophoresis and liquid chromatography/tandem mass spectrometry. One of the down-regulated proteins in OSCC was identified as tetranectin, which is a protein encoded by the CLEC3B gene (C-type lectin domain family 3, member B). We further tested the protein level in serum and saliva from patients with lymph-node metastatic and primary OSCC. Tetranectin was found significantly under-expressed in both serum and saliva of metastatic OSCC compared to primary OSCC. Our results suggest that serum or saliva tetranectin may serve as a potential biomarker for metastatic OSCC. Other candidate serum biomarkers for OSCC included superoxide dismutase, ficolin 2, CD-5 antigen-like protein, RalA binding protein 1, plasma retinol-binding protein and transthyretin. Their clinical utility for OSCC detection remains to be further tested in cancer patients.
Keywords: oral squamous cell carcinoma; serum proteomics; tetranectin; disease biomarker

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Arellano-Garcia, M.E.; Li, R.; Liu, X.; Xie, Y.; Yan, X.; Loo, J.A.; Hu, S. Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer. Int. J. Mol. Sci. 2010, 11, 3106-3121.

AMA Style

Arellano-Garcia ME, Li R, Liu X, Xie Y, Yan X, Loo JA, Hu S. Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer. International Journal of Molecular Sciences. 2010; 11(9):3106-3121.

Chicago/Turabian Style

Arellano-Garcia, Martha E.; Li, Roger; Liu, Xiaojun; Xie, Yongming; Yan, Xiaofei; Loo, Joseph A.; Hu, Shen. 2010. "Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer." Int. J. Mol. Sci. 11, no. 9: 3106-3121.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert